Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the ...

Catherine Gaffigan, MD, Elevance Health's President of Health Solutions, discusses value-based care initiatives and ...

Prostate cancer has been of the major areas of research for radioligand therapies. Last year, Novartis officials estimated that the March 28, 2025, FDA approval for Pluvicto in metastatic ...

Higher baseline monocyte counts, along with preserved basophils and low C-reactive protein, independently predict complete remission on anti-IgE therapy for CSU.

A US-focused cohort study published in 2023 showed similar trends, with a higher AA incidence observed among women (range, 108.53-118.56) vs men (range, 63.68-72.09) and adults (range, 95.45-102.63) ...

Experts discuss how treatment strategies for NSCLC differ between resectable and metastatic disease, emphasizing a multimodal, curative approach in early-stage cancer versus personalized systemic ...

Most clinicians in the US see lipoprotein A (Lp [a]) as a useful tool in cardiovascular risk stratification, according to a new survey. However, the respondents were less certain about what to do with ...

Kathrin Dvir, MD, MSc, discusses how biomarker-driven care, targeted therapies, and evolving sequencing are shaping modern breast cancer treatment.

Moreover, small shifts in clinic numbers can have outsized effects in states with relatively few providers. For instance, the closure of even a single clinic in Alaska, Nebraska, or Rhode Island can ...

Patients with therapeutic intensification of pharmacological pressure-unloading therapy had marked improvements in cardiac load, the study found, as demonstrated by reductions in N-terminal pro-B-type ...

Updated NCCN pediatric STS guidelines emphasize risk stratification, imaging, multimodal therapy, and clinical trial enrollment to improve outcomes. The National Comprehensive Cancer Network (NCCN) ...

Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies.